Calquence (acalabrutinib) is a kinase inhibitor in
Post# of 148292
(Total Views: 609)
Posted On: 06/05/2020 8:00:55 PM
Re: reallypeople? #36836
Calquence (acalabrutinib) is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Common side effects of Calquence include:
anemia,
low platelet count (thrombocytopenia),
headache,
low white blood cell count (neutropenia),
diarrhea,
fatigue,
muscle pain,
bruising,
nausea,
abdominal pain,
constipation,
vomiting,
rash,
and nosebleed.
Common side effects of Calquence include:
anemia,
low platelet count (thrombocytopenia),
headache,
low white blood cell count (neutropenia),
diarrhea,
fatigue,
muscle pain,
bruising,
nausea,
abdominal pain,
constipation,
vomiting,
rash,
and nosebleed.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼